Syndax Pharmaceuticals enters the back half of May with one of the highest short burdens in small-cap biotech — yet the analysts covering it remain uniformly bullish, pointing to a gap between positioning and conviction that is the central tension this week.
Short interest is deeply embedded and has been edging higher this week. At roughly 28.7% of free float, the short book is near the top of its recent range and only marginally below the 30% levels seen in early April. The day-to-day move on May 12 added about 2.2%, nudging the short score to 73.3 — its highest reading across the past two weeks of daily data. That score ranks in just the 9th percentile of the universe, meaning almost every other stock has fewer bearish signals stacked against it. Days to cover run above 12, so any meaningful covering event would take time to play out.
The borrow market, however, tells a slightly different story about urgency. Availability remains loose — cost to borrow is running at just 0.43%, barely changed over the week and well within its 30-day range. There is no squeeze pressure in the lending pool. Options positioning reinforces the calm: the put/call ratio is 0.31, essentially in line with its 20-day average of 0.30 and far from the 0.93 annual high. Calls heavily outnumber puts, and the z-score is near zero. Short sellers have the float pinned down, but they are not paying up for borrows and the options market is not hedging for a violent move.
The Street is unmoved by the short overhang. Every analyst covering SNDX carries a Buy or Overweight equivalent. UBS trimmed its target modestly to $37 on May 13 while keeping its Buy rating, and Barclays moved in the opposite direction earlier in May, lifting to $37 from $35. The mean target across the coverage sits at $39.25 — nearly double the current $20.41 close — implying the Street sees roughly 92% upside from here. Goldman Sachs raised its target to $34 in April, and JP Morgan pushed to $45 back in March. That degree of collective bullishness, sustained against a stock down 16% over the past month, suggests analysts are focused on the revumenib pipeline rather than near-term price action. The bull case centres on revumenib's complete response rates in acute leukemias and Syndax's first-mover advantage in frontline therapy; the bear case flags the expanded boxed warning that triggered the stock's April drop and the inherent binary risk of clinical-stage oncology.
Institutional holders are broadly stable. BlackRock holds about 9.3% and Vanguard 7%, with State Street adding 743,000 shares in the most recent reporting period through April 30. There is no sign of large-scale institutional exit. Insider activity on file is dated — the most recent trades logged are routine executive sales in early February, near the same price range the stock occupies today. Those transactions carry low significance scores and offer no new signal; the insider data effectively goes quiet after February 9.
The next scheduled catalyst is a Q2 earnings call on June 10. The most recent earnings event on April 30 produced a sharp single-day fall of 7.4%, though the stock had largely recovered its five-day loss to near flat by the end of that week. The print before that, in early May, saw a 3.5% gain. With the short score ticking to a new two-week high even as cost-to-borrow stays subdued, the key question heading into June is whether any clinical update or data readout for revumenib narrows the gap between the Street's $39 consensus and the stock's current $20 handle.
See the live data behind this article on ORTEX.
Open SNDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
